Abstract
. Ž . ventricular function LVEF 36 " 3% due to dilated cardiomyopathy DCM and in biopsies from 12 patients with suspected myocardial Ž . disease but normal cardiac function LVEF 62 " 2% . Two biopsies per patient were pooled, RNA was extracted and reverse-transcribed after addition of an AT cRNA standard. AT standard and wild-type RNA were amplified with the same primers in the same PCR tube. 1 1
The PCR products were hybridized to a microtiter plate and detected and quantitated by an ELISA system. Glyceraldehyde phosphate Ž . dehydrogenase GAPDH mRNA was determined in the same samples as AT mRNA. Results: In the biopsies from 16 patients with 1 Ž heart failure, a 68% decrease in AT mRNA content was found in comparison with 12 controls heart failure 94 " 15 AT mRNA 1 1 . copiesrng RNA; controls 297 " 45; P -0.001 . Relating AT mRNA content to GAPDH mRNA confirmed the specific decrease in AT 1 1 Ž . mRNA AT rGAPDH: heart failure 1.3 " 0.15; controls 3.4 " 0.5; P -0.002 . The best correlation between AT mRNA content and 1 1 Ž . clinical parameters was found for right ventricular ejection fraction r s 0.59, P -0.01 . Conclusions: The quantitative RT-PCR procedure indicated a loss of ventricular AT mRNA in human heart failure which corresponds to the loss of AT protein described
Introduction
Ž . Cardiac angiotensin receptors ATR mediate the direct Ž . effects of angiotensin II Ang II on the heart. Cardiac Ang II effects probably play a role in remodelling after myocardial infarction, in the development of ventricular hypertrophy and in the morphological changes associated with Ž heart failure. In the human heart, both ATR subtypes AT 1 . w x and AT are expressed 1-3 . Ang II, via AT , exerts 2 1 hypertrophic and positive inotropic effects in the myocardium from experimental animals and in human atrial Regulation of cardiac AT has already been reported in 1 a number of physiological conditions. Upregulation was w x found in hypertrophic and ischaemic states 12-14 , whereas downregulation of cardiac AT was found in rat ( )w x and human heart failure 1,15,16 . Human atrial and ventricular AT differ in expression level, which is higher in 1 w x w x the atria 1,17 , and their effects on contractile function 8 . Whereas AT downregulation in human atria at end-stage 1 heart failure has been well described at the mRNA and protein level, fewer data are available on ventricular AT 1 w x regulation 1,18,19 . So far, ventricular AT regulation has 1 only been investigated in explanted hearts from transplant recipients, which limits the conclusions to end-stage heart failure. To assess the regulation of human ventricular AT 1 in heart failure of different stages, particularly in nonterminally-diseased patients, AT mRNA content must be 1 assessed in endomyocardial biopsies. This approach has been used in the present study. A novel quantitative PCR w x procedure 20 enabled the determination of absolute mRNA copy numbers with a low variance. The study is the first to compare ventricular AT mRNA content in 1 endomyocardial biopsies from patients with heart failure due to dilated cardiomyopathy and normal systolic cardiac function.
Methods
AT mRNA was measured in endomyocardial biopsies 1 from 16 patients with heart failure due to dilated cardiomyopathy undergoing diagnostic cardiac catheterization and right ventricular endomyocardial biopsy. All patients had Ž . decreased left ventricular function mean LVEF 36 " 3% and increased ventricular volumes in the presence of a Ž . normal left ventricular wall thickness Table 1 . Most Ž . patients belonged to the NYHA class II n s 9 , 5 to class III, 1 to class IV and 1 to class I. Patients were treated Ž . Ž . with digitalis n s 9 , ACE inhibitors n s 14 , and diuret-Ž . ics n s 9 . Twelve patients undergoing cardiac catheterization and biopsy for suspected myocarditis based on atypical chest pain, arrhythmia andror borderline echocardiographic ventricular volumes and function who turned out to have normal right and left ventricular function at cardiac catheterization, without signs of inflammatory disease in the biopsy, were used as controls. These patients were treated with digitalis for supraventricular arrhythmia Ž . Ž . ns5 and with ACE inhibitors n s 6 andror diuretics Ž . ns3 for hypertension. Significant coronary artery disease was excluded by coronary angiography in all cases. Informed consent was obtained from all patients before tissue sampling. The study was approved by the Ethical Committee at the Virchow Clinic. The investigation conforms with the declaration of Helsinki.
Cardiac catheterization in all patients included the measurement of left and right ventricular pressures, cardiac output, coronary angiography and the determination of right and left ventricular volumes and ejection fraction by Ž . biplane angiography after injection of 30 right or 40 Ž . left ml of non-ionic contrast medium. Volumes were determined according to the Simpson and Ferlinz method w x which were previously validated in our setting 21-23 . The left ventricular mass was calculated from the end-diastolic wall thickness in LAO projection and the left ventricular end-diastolic volume.
Right ventricular endomyocardial biopsies were taken at cardiac catheterization by a transfemoral approach using a Ž 7-French Signus Bioptome 2.2 mm = 104 cm, Signus . GmbH, D-63755 Alzenau, Germany . The bioptome was directed versus the right ventricular septum by standard Ž techniques. Two pieces were taken for histological HE . and van Giesson staining and immunohistological examination and two were used for mRNA quantitation. Routine immunohistology included staining with antibodies for vi-Ž . mentin, alpha smooth muscle actin, panT-cells UCL1 , Ž . Ž . Ž B-lymphocytes CD21 and macrophages KP1 Dako, . 22047 Hamburg, Germany . Patients with histological signs of myocarditis were excluded from the study.
Biopsies were frozen immediately on dry ice and stored at y708C until analysis. Biopsies from controls and heart Ž . failure patients did not differ in wet weight Table 2 . Two biopsies per patient were pooled, RNA was extracted with Ž . RNAzol B Lorei q Paesel, Germany and subjected to a w x DNAse digest 20 . Yields of RNA before and after DNase digest were comparable in the patients with heart failure and controls. From each sample, 250 ng RNA were mixed with internal AT cRNA standard and reverse-transcribed 1 with 300 ng random hexamers and 100 U Superscripte Ž . Gibco BRL, Germany . To control the efficient digestion of DNA, all samples were run after digestion in a PCR Ž . with the specific primers for AT see below before 1 reverse transcription and with primers for pyruvate dehy-Ž . drogenase PDH which yield bands of different length at w x the DNA and RNA level after reverse transcription 1 . All samples were negative for the AT and PDH DNA frag- About 40 000 copies of the standard cRNA were reverse-transcribed with 250 ng sample RNA. A regression line was established by adding the same amount of stan-Ž dard to increasing wild-type concentrations 50-1000 ng . sample RNA . Over a relatively small measuring range, a linear increase in the wild-typerstandard ratio resulted Ž . Fig. 1b . Linearity is probably due to the high structural identity and thereby identical amplification efficiency of wild type and standard as well as to the fact that only a small measurement must be covered, since the changes in AT expression are relatively small. Based on this regres-1 sion line and the known amount of standard in each sample, the amount of wild type was calculated. To ensure that potential changes in the AT mRNA were not due to copies standard and wild type template were co-amplified in one tube. Aliquots were removed after 31, 32, 33, 34, 35, 36 and 37 cycles and the products Ž . were quantitated in the microtiter plates. Plotting specific ELISA-OD optical density, =1000 against number of cycles in semilogarithmic manner shows identical efficiencies for standard and wild-type amplification. Right panel: Calculated ratios of wild-typerstandard for the reverse transcription and co-amplification of increasing amounts of wild type RNA together with 40 000 copies standard in each tube. A linear increase in the ratios of wild-typerstandard is observed over the whole measurement range. Table 3 Variance for the quantitation of AT mRNA in ventricular biopsies 1 Step Three biopsies of 10 mg were taken from an explanted heart. To Ž . determine the Õariance between the samples including PCR variance , the 3 tissue samples were extracted and then reverse-transcribed in the same RT reaction. Each of them was analysed by a single PCR. To assess Ž . the RT Õariance including PCR variance , each sample was reverse-tran-Ž scribed in 3 different RT's on 3 different days with 3 different master . mixes and each RT product was quantitated by a single PCR. To obtain PCR Õariance, one sample was reverse-transcribed in 3 RTs, each followed by 3 different PCRs. To assess well-to-well Õariance and the variance of ELISA detection, the same PCR amplicons were determined in 2 different wells on the ELISA plate and measurements of the same wells in the ELISA reader were repeated twice. mRNA degradation, the AT mRNA content in the atria 1 and ventricles was related to the stably expressed GAPDH mRNA. The mRNA for GAPDH was amplified by PCR Ž .
cycles and the amplicons were quantitated by HPLC.
To analyze the variability of the different steps of the procedure, 3 biopsies from about 10 mg were taken from an explanted heart. RNA was extracted from each sample, Ž subjected to 3 different reverse transcriptions RT, result-. ing in 9 different RTs and each RT product was subjected Ž .Ž . to 3 different PCRs 27 PCRs Table 3 . If one sample was reverse-transcribed in one RT, followed by 3 different PCRs, a mean PCR variability of about 10% resulted. If the 3 tissue samples were extracted and then reverse-tran-Ž scribed in the same RT reaction same master mixes and . chemicals, identical conditions and each of them was analysed by a single PCR, the variability between the Ž . different tissue samples including the PCR variability amounted to about 15%. If we reverse-transcribed each Ž sample in 3 different RT's on 3 different days with 3 . different master mixes and quantitated each RT product by a single PCR, variability amounted in the mean to 25%. This clearly indicates that the largest variance is introduced by the variability of the RT procedure. We reduced this variance in our study by reverse-transcribing all samples in a single RT using the same chemicals and master mixes.
Statistics
Data are given as mean and s.e.m. Wilcoxon tests have been used to compare groups. In addition, confidence intervals for the mean values have been calculated using the SPSS programme. Pearson's correlation coefficients were calculated between AT expression and haemody-1 namic parameters.
Results
Patients and controls differed significantly in ventricular AT mRNA expression. The number of AT copies 1 1 amounted to 94 " 15 copiesrng RNA in the biopsies from Ž . failing hearts versus 297 " 45 P -0.001 in the control Ž . group Fig. 2 , corresponding to a 68% loss of AT 1 mRNA. 95% confidence intervals ranged from 208-385 copiesrmg RNA in the control group and 64-123 copiesrmg RNA in the heart failure group.
The mRNA for GAPDH was unchanged in heart failure Ž . and in controls Fig. 2 . If AT mRNA was related to 1 GAPDH mRNA, the difference between controls and heart failure was maintained. The AT rGAPDH ratio amounted Ž . Ž . biopsies from heart failure HF and from control patients Con . AT 1 mRNA is significantly decreased, by 68%, in heart failure. No significant difference in the GAPDH expression was found between both groups, whereas the AT rGAPDH ratio was significantly decreased in the heart 
Discussion
Using a novel quantitative PCR technique, we determined the AT mRNA content in human right ventricular 1 Ž . endomyocardial biopsies and found a significant 68% decrease in AT mRNA in human heart failure. Relating 1 AT mRNA to the mRNA of the stably expressed GAPDH 1 mRNA confirmed the specific downregulation of ventricular AT in heart failure. AT mRNA content was signifi- 1 1 cantly correlated with functional parameters of the right and left ventricle. To determine the AT mRNA content, we used a 1 quantitative RT-PCR procedure based on an internal AT 1 cRNA standard, liquid-phase hybridization of PCR products to a 96-well microtiter plate and quantitation by an w x ELISA system 20 . The PCR-ELISA system has a low variance of about 10%, whereas a variance of about 25% is due to the combination of RT and PCR. The method allows for the determination of absolute copy numbers although limited by the assumptions that have to be made for calculations. Precise quantitation of the cRNA standard remains a problem that is inherent to most quantitative PCR approaches as well as the difficulty of ensuring that standard and wild type are reverse-transcribed with the same efficiency. The high structural similarity between standard and wild type including their surrounding DNA sequences favours similar transcription rates. For use in biopsies, we have optimized the RT procedure and the amount of standard to be added and we transcribed all samples in a single RT reaction.
To exclude non-specific degradation of mRNA, we related AT to GAPDH mRNA, confirming the selective ( )lation of AT by its agonist has already been described in 1 w x glomerular mesangial cells 26 . Relevant cardiac Ang II levels may persist in heart failure in spite of ACE inhibitor w x therapy since cardiac ACE is upregulated 27 and not all ACE inhibitor dosages inhibit tissue ACE effectively over 24 h. Furthermore, human heart chymase may generate intracardiac Ang II, particularly in the presence of elevated Ang I concentrations, and thus may maintain relevant cardiac Ang II levels in spite of ACE inhibitor therapy w x 28 . Continuing action of chymase in the presence of ACE inhibitors may explain the lack of a correlation between AT expression and ACE inhibitor therapy. 1 The weak correlation between AT expression and clini-1 cal parameters is not surprising given the relatively small number of patients studied and the variance in medical therapy. The relatively small number of patients studied within each group together with the clustering of ejection fractions around the mean value in each group is probably the reason for the lack of a correlation between AT 1 expression and ejection fraction within the control or DCM group. There was also no correlation with left ventricular mass or wall thickness, probably because all DCM patients had enlarged ventricles, in the presence of a normal wall thickness and the increase in mass reflected more the process of dilatation than hypertrophy. However, a significant correlation with right and also left ventricular ejection fraction was found, indicating a functional relevance of AT -mediated effects in the human heart. Since we have 1 used right ventricular endomyocardial biopsies and a decrease in right ventricular ejection fraction is a hallmark of the progression of dilated cardiomyopathy, the predominant correlation of AT expression with right ventricular 1 ejection fraction seems reasonable.
The fact that we have used right ventricular endomyocardial biopsies to study a disease that is mainly characterized by left ventricular dysfunction represents somewhere a limitation of the study. However, biochemical changes in the right ventricular septum have already been shown to correlate with functional parameters of the left ventricle w x 29,30 .
A second limitation arises from the fact that AT mRNA 2 was not quantitated. AT seems to play a role in develop-2 mental biology and may counteract AT in rat and mouse 1 w x cell lines, in transfected vascular smooth muscle cells 9 , w x neonatal rat myocytes 31 , or rat coronary endothelial w x cells 10 . However, all cardiac actions of Ang II that have been revealed so far by subtype selective blockers in a number of intact animal models and in humans or have been found in the adult rodent or human heart are mediated by AT . Therefore, we focused in the present clinical 1 investigation first on AT . 
